Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
August 16, 2026 6:36 am ET
Delayed at least 20 minutes

Latest news, events & financials

August 6, 2026

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

August 4, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

July 29, 2026

Merck Announces Fourth-Quarter 2026 Dividend

View all

August 04, 2026

Earnings

Q2 2026 Earnings Call

Webcast 2Q26 Merck Earnings Presentation 2Q26 Merck Earnings Announcement 2Q26 Merck Other Financial Disclosures Transcript Form 10-Q 2Q26 Other Financial Disclosures (Excel) 2Q26 Prepared Remarks

August 03, 2026

Webcast

Investor Event at AIDS 2026, the 26th International AIDS Conference

Webcast Presentation Transcript

June 09, 2026

Webcast

47th Annual Goldman Sachs Global Healthcare Conference

Webcast Transcript

June 04, 2026

Webcast

Jefferies Global Healthcare Conference

Webcast Transcript

June 01, 2026

Webcast

Investor Event at ASCO 2026

Webcast Transcript Presentation

May 26, 2026

Webcast

2026 Annual Meeting of Shareholders

Webcast Presentation Vote Results Transcript

April 30, 2026

Earnings

Q1 2026 Earnings Call

Webcast 1Q26 Merck Earnings Presentation 1Q26 Merck Earnings Announcement 1Q26 Merck Other Financial Disclosures Transcript Form 10-Q 1Q26 Other Financial Disclosures (Excel) 1Q26 Prepared Remarks

March 25, 2026

Webcast

Merck to Acquire Terns Pharmaceuticals

Webcast Presentation Transcript

March 03, 2026

Webcast

TD Cowen 46th Annual Health Care Conference

Webcast Transcript

February 03, 2026

Earnings

Q4 2025 Earnings Call

Webcast 4Q25 Merck Earnings Presentation 4Q25 Merck Earnings Announcement 4Q25 Merck Other Financial Disclosures Transcript Form 10-K 4Q25 Other Financial Disclosures (Excel) 4Q25 Prepared Remarks

January 12, 2026

Webcast

44th Annual J.P. Morgan Healthcare Conference

Webcast Transcript Presentation

View all

2Q26 Merck Earnings Presentation

2Q26 Merck Other Financial Disclosures

2Q26 Other Financial Disclosures (Excel)

2Q26 Prepared Remarks

Investor Event at ESMO 2026

October 26, 2026

Dial: (800) 369-2154 or (517) 308-9422

Access Code: 8984239

Merck office building and research site in South San Francisco

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

50+

Phase III programs

30+

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Image showing microbes in a lab dish on the left and earth on the right

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

Download our Sustainability financing documents:

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q2 2026 financial results

Merck’s (NYSE: MRK) Q2 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q2 worldwide sales of $16.6 billion. “We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Rob Davis, chairman and […]

Innovation

Our Q1 2026 financial results

Merck’s (NYSE: MRK) Q1 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q1 worldwide sales of $16.3 billion. “We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Rob […]

Two scientists looking at liquid in vial

Innovation

Our Q4 and full-year 2025 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q4 worldwide sales of $16.4 billion. Full-year 2025 worldwide sales were $65.0 billion. “In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that […]

Innovation

Our Q2 2026 financial results

Next: Our Q2 2026 financial results

Innovation

Our Q1 2026 financial results

Next: Our Q1 2026 financial results

Innovation

Our Q4 and full-year 2025 financial results

Next: Our Q4 and full-year 2025 financial results

Unsubscribe from email alerts

For questions, please contact our team.

Who we are

Investor relations